Aldea Pharmaceuticals announces closure of $24M Series B equity financing Aldea Pharmaceuticals.
Since there is absolutely no antidote treatment available for alcohol toxicity, individuals with acute alcoholic beverages intoxication must await the alcohol to be metabolized from their systems before they could be discharged from the ER. The usage of Advertisement-6626 in the ER setting has the potential to stabilize sufferers suffering from acute alcohol toxicity and more rapidly improve the signs or symptoms of intoxication than looking forward to alcohol metabolism, simplifying patient care thereby. We likewise have the opportunity to apply our scientific strategy in the treatment of sufferers with Fanconi anemia, a uncommon genetic disease characterized by chromosomal instability, bone marrow failure and an increased risk of cancer. (more…)